Updated data from the FORTE trial of carfilzomib plus lenalidomide or cyclophosphamide for myeloma

Interim results of RELEVANCE trial in follicular lymphoma

Disease control in advanced Hodgkin lymphoma

Improved OS with obinutuzumab in the CLL11 study

Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results

Mapping 3D genome dynamics in B cells

Update on bb2121 for relapsed myeloma

Repurposing selective PDE5 inhibitors as anti-cancer agents

First results of DREAM trial of frontline durvalumab for mesothelioma

Results from the phase I ICONIC trial

Phase II results of olaparib and abiraterone for mCRPC

Global treatment pattern variations in HCC